Molecular structure of Triclabendazole, CAS Number: 68786-66-3
Triclabendazole (CAS 68786-66-3)
Alternate Names:
5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole
Application:
Triclabendazole is an anthelminitic
CAS Number:
68786-66-3
Purity:
≥98%
Molecular Weight:
359.65
Molecular Formula:
C14H9Cl3N2OS
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Triclabendazole is a veterinary anthelmintic agent primarily employed in the treatment and control of fascioliasis, a parasitic infection caused by liver flukes, most notably Fasciola hepatica and Fasciola gigantica. Its mode of action is distinguished by its ability to specifically target and inhibit the enzyme beta-tubulin, which is critical for microtubule formation in the cells of these parasites. By binding to beta-tubulin, Triclabendazole disrupts the parasite′s cellular structure and function, leading to impaired energy metabolism, reduced motility, and ultimately, the death of the parasite.
Triclabendazole (CAS 68786-66-3) References
- Triclabendazole: new skills to unravel an old(ish) enigma. | Fairweather, I. 2005. J Helminthol. 79: 227-34. PMID: 16153316
- Triclabendazole for the treatment of fascioliasis and paragonimiasis. | Keiser, J., et al. 2005. Expert Opin Investig Drugs. 14: 1513-26. PMID: 16307491
- Understanding triclabendazole resistance. | Brennan, GP., et al. 2007. Exp Mol Pathol. 82: 104-9. PMID: 17398281
- Triclabendazole progress report, 2005-2009: an advancement of learning? | Fairweather, I. 2009. J Helminthol. 83: 139-50. PMID: 19366485
- Triclabendazole sulfoxide causes stage-dependent embryolethality in zebrafish and mouse in vitro. | Boix, N., et al. 2015. PLoS One. 10: e0121308. PMID: 25793498
- Current Threat of Triclabendazole Resistance in Fasciola hepatica. | Kelley, JM., et al. 2016. Trends Parasitol. 32: 458-469. PMID: 27049013
- Solving the Delivery Problems of Triclabendazole Using Cyclodextrins. | Real, D., et al. 2018. AAPS PharmSciTech. 19: 2311-2321. PMID: 29845501
- Triclabendazole for the treatment of fascioliasis. | Thakare, R., et al. 2019. Drugs Today (Barc). 55: 743-752. PMID: 31942877
- Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures. | Marcos, L., et al. 2021. Expert Rev Anti Infect Ther. 19: 817-823. PMID: 33267701
- Fasciola Hepatica Induced Hepatic Abscess Treated with Triclabendazole. | Park, HJ., et al. 2021. Korean J Gastroenterol. 77: 39-44. PMID: 33495431
- Triclabendazole Treatment Failure for Fasciola hepatica Infection among Preschool and School-Age Children, Cusco, Peru1. | Morales, ML., et al. 2021. Emerg Infect Dis. 27: 1850-1857. PMID: 34152949
- Triclabendazole Induces Pyroptosis by Activating Caspase-3 to Cleave GSDME in Breast Cancer Cells. | Yan, L., et al. 2021. Front Pharmacol. 12: 670081. PMID: 34305590
Inhibitor of:
ALDH2, Cyp2c37, D16H22S680E, HPPDL, METH-2, Trp5, and Trp7.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Triclabendazole, 100 mg | sc-213105 | 100 mg | $106.00 | |||
Triclabendazole, 1 g | sc-213105A | 1 g | $122.00 |